Back to search results

Childhood Cancer Survivor Study

This study, called the Childhood Cancer Survivor Study (CCSS), is looking at the long-term health effects of cancer and its treatments in people who had cancer as children or young adults. Researchers want to understand how different treatments like radiation, chemotherapy, and surgery might affect your health later in life. They will compare the health of about 50,000 cancer survivors with 10,000 of their siblings to see these long-term effects. The main goal is to understand how your health is affected by your disease, the treatments you received, and your genes, with results being looked at 25 years after diagnosis. This study is currently unclear about its recruitment status.

Study design
This is an observational study involving about 50,000 cancer survivors and 10,000 sibling controls. It is a retrospective cohort study, meaning it looks back at past health information.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary health outcomes will be measured at 25 years after diagnosis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01120353

Childhood Cancer Survivor Study

Recruiting
Not specifiedAll AgesObservational
St. Jude Children's Research Hospital
~50,000 participants
Updated 2026-06-17 on ClinicalTrials.gov

At a glance

Recruiting sites
28 of 31 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To characterize survivors' health outcomes with respect to disease-, treatment, and genetic-related factors.
Measured over 25 years

Conditions

Cancer

Explore related trials

Bone NeoplasmCentral Nervous System NeoplasmKidney NeoplasmLeukemiaLymphomaNeuroblastomaRhabdomyosarcomaSoft Tissue SarcomaWilms Tumor

Where it's being run

31 sites across 18 states
California6
Texas4
Minnesota3
Illinois2
New York2
Pennsylvania2
Alabama1
Colorado1

Study leadership

  • Gregory T. Armstrong, MD, MSCE · PRINCIPAL_INVESTIGATOR · St. Jude Children's Research Hospital

Who to contact

Gregory T. Armstrong, MD, MSCE
[email protected]
888-226-4343
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Five-year survival following diagnosis of leukemia, lymphoma, CNS tumor, bone tumor, Wilms tumor, neuroblastoma, or soft tissue sarcoma before age 21 years between January 1, 1970 and December 31, 1986 at one of participating centers.
Five-year survival following diagnosis of leukemia, lymphoma, CNS tumor, bone tumor, kidney tumor, neuroblastoma, or rhabdomyosarcoma before age 21 years between January 1, 1987 and December 31, 1999 at one of participating centers.
English- or Spanish-speaking and living in the U.S. or Canada at the time of diagnosis.

Exclusion

Diagnosis of non-malignant tumors (i.e., Langerhans cell histiocytosis, meningioma, craniopharyngioma, etc.) treated with radiation and/or chemotherapy.
Non-English speaking or residence outside the US or Canada.
For comparison purposes, a group of sibling controls will be identified to represent a stratified random sample based on the distribution of survivors with regard to cancer diagnosis, age, sex, race, and geographic location.

What this trial measures

  • To characterize survivors' health outcomes with respect to disease-, treatment, and genetic-related factors.25 years